High Prevalence of Anti-β2 Glycoprotein I Antibodies in Patients with Ischemic Heart Disease

References

• Galli M., Comfurius P., Maassen C., Hemker H. C., de M. H., Baets P., van Breda-Vriesman J. C., Barbui T., Zwaal R. F.A., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547
   PubMed Web of Science ®Google Scholar
• McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-Glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 1990; 87: 4120–4124
   PubMed Web of Science ®Google Scholar
• Schousboe I. β2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086–1091
   PubMed Web of Science ®Google Scholar
• Mc Nally T., Mackie I. J., Machin S. J., Isenberg D. A. Increased levels of β2-glycoprotein-I antigen and β2-glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br. J. Rheumatol. 1995; 34: 1031–1034
   PubMedGoogle Scholar
• Martinuzzo M. E., Forastiero R. R., Carreras L. O. Anti β2-glycoprotein I antibodies: Detection and association with thrombosis. Br. J. Haematol. 1995; 89: 397–402
   PubMed Web of Science ®Google Scholar
• Horbach D. A., van Oort E. R., Donders C. J.M.R., Derksen H. W.M., de Groot P. G. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb. Haemost. 1996; 76: 916–924
   PubMed Web of Science ®Google Scholar
• Gharavi A. E., Sammaritano L. R., Wen J., Elkon K. B. Induction of antiphospholipid antibodies by immunization with β2-glycoprotein I (apolipoprotein H). J. Clin. Invest. 1992; 90: 1105–1109
   PubMed Web of Science ®Google Scholar
• Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., Allegri F., Balestrieri G., Valesini G., Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2-glycoprotein 1) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmunity 1994; 7: 441–455
   PubMed Web of Science ®Google Scholar
• George J., Shoenfeld Y. The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis. Lupus 1997; 6: 559–560, (editorial)
   PubMed Web of Science ®Google Scholar
• Levy R. A. Clinical manifestations of aPL syndrome. Lupus 1996; 5: 393–397
   PubMed Web of Science ®Google Scholar
• Morton K. E., Krilis A. S., Baron D. W., Gaughan T. P., Daggard G. E., Hickie J. B., Chesterman C. N. Coronary artery by pass graft failure: an autoimmune phenomenon?. Lancet 1986; 2: 1353–1357
   PubMed Web of Science ®Google Scholar
• Chiarugi L., Prisco D., Capanni M., Antonucci E., Fedi S., Alessandrello Liotta A., Margheri M., Giglioli C., Dabizzi R. P., Sinlonetti I., Abbate R., Gensini C. F. Anticardiolipin antibodies: a risk factor for restenosis after percutaneous transluminal angioplasty. Autoimmunity 1998; 27: 141–148
   PubMed Web of Science ®Google Scholar
• Vaarala O., Puurunen M., Mänttäri M., Manninen V., Aho K., Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb. Haemost. 1996; 75: 456–459
   PubMed Web of Science ®Google Scholar
• Piette J. C. 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a “mission impossible”?. Lupus 1996; 5: 354–363
   PubMed Web of Science ®Google Scholar
• Baiestrieri G., Tincani A., Spatola L., Allegri F., Prati E., Cattaneo R., Valesini G., Del Papa N., Meroni P. L. Anti-beta2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995; 4: 122–130
   PubMed Web of Science ®Google Scholar
• Neri Serneri G. G., Prisco D., Martini F., Gori A. M., Brunelli T., Poggesi L., Rostagno C., Gensini G. F., Abbate R. Acute T-cell activation is detectable in unstable angina. Circulation 1997; 95: 1806–1812
   PubMed Web of Science ®Google Scholar
• Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. L., Rebuzzi A. G., Pepys M. B., Maseri A. The prognostic value of C-reactive protein and serum amyloid, a protein in severe unstable angina. N. Engl. J. Med. 1994; 331: 417–424
   PubMed Web of Science ®Google Scholar
• Simantov R., LaSala J. M., Lo S. K., Gharavi A. E., Sammaritano L. R., Salmon J. E., Silverstein R. L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 1995; 96: 2211–2219
   PubMed Web of Science ®Google Scholar
• Del Papa N., Raschi E., Catelli L., Khamashta M. A., Ichikawa K., Tincani A., Ralestrieri G., Meroni P. L. Endothelial cells as a target for antiphospholipid antibodies: role of anti-β2-glycoprotein 1 antibodies. Am. J. Reproduct. Immunol. 1997; 38: 212–217
   PubMed Web of Science ®Google Scholar
• Biasucci L. M., Ciliberto G., Liuzzo G., Altamura S., Monaco C., Quaranta G., Caligiuri G., Vitelli A., Maseri A. Elevated serum concentrations of interleukin-6 in unstable angina. Circulation 1995; 92(supplement I)I–664, (abstract 3186)
   Google Scholar